X0508 4 2026-01-28 0001855175 Contineum Therapeutics, Inc. CTNM 0002065965 Watkins Tim 3565 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121 1 CMO & Head of Development 1 Class A Common Stock 2026-01-28 4 M 0 3611 4.50 A 3611 D Class A Common Stock 2026-01-28 4 S 0 2800 14.0861 D 811 D Class A Common Stock 2026-01-28 4 S 0 811 14.4848 D 0 D Stock Option (right to buy) 4.50 2026-01-28 4 M 0 3611 0 D 2035-04-27 Class A Common Stock 3611 252778 D Stock Option (right to buy) 14.26 2026-01-30 4 A 0 160000 0 A 2036-01-29 Class A Common Stock 160000 160000 D These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. /s/ Peter Slover, Attorney-in-Fact 2026-01-30